New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT06126666

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 21 times

Summary

This early-phase trial is testing a new drug called ABL103 in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and check for side effects. About 96 participants will receive the drug to see if it can help control their cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam, Seoul, 13620, South Korea

    Contact

    Contact Email: •••••@•••••

  • Seoul National University Hospital

    NOT_YET_RECRUITING

    Seoul, Seoul, 03080, South Korea

    Contact Email: •••••@•••••

  • Sevrance Hospital

    RECRUITING

    Seoul, South Korea, 03722, South Korea

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.